Crispr Therapeutics shares tumble after significant earnings miss
Joseph Edward Sweeney, President of AWM Products & Services at Ameriprise Financial Inc. (NYSE:AMP), executed a significant stock transaction recently. On February 19, 2025, Sweeney sold 4,636 shares of Ameriprise Financial common stock. The sale was conducted at an average price of $539.07 per share, resulting in a total transaction value of approximately $2.5 million. The transaction comes amid Ameriprise’s impressive 25% surge in share price over the past six months, with the stock currently trading near its Fair Value according to InvestingPro analysis. Following this sale, Sweeney retains ownership of 7,237 shares directly.
Additionally, Sweeney’s holdings in the Ameriprise Financial Stock Fund under the company’s 401(k) plan are estimated at 293.73 shares. The number of shares in this plan is subject to change based on the Ameriprise stock price. The company has maintained dividend payments for 21 consecutive years, with a recent dividend yield of 1.09% and impressive 9.6% dividend growth over the last year. Get deeper insights into insider trading patterns and comprehensive analysis with InvestingPro’s detailed research reports.
In other recent news, Ameriprise Financial reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $9.54 compared to the forecasted $9.17. The company also saw a 13% year-over-year increase in revenue, reaching $4.5 billion. Despite these positive results, the Advice & Wealth Management (AWM) segment experienced weaker earnings and margins. Analysts from Keefe, Bruyette & Woods raised their EPS estimates for 2025 and 2026, citing improved growth and trends, and increased their price target for Ameriprise to $570 while maintaining a Market Perform rating. Meanwhile, Piper Sandler adjusted their price target to $442 from $415 but maintained an Underweight rating, highlighting concerns about the sustainability of AWM’s operating margin. In governance news, Ameriprise announced the appointment of Glynis A. Bryan to its Board of Directors, effective March 1, 2025, enhancing its governance and oversight capabilities. These developments reflect the company’s ongoing strategic initiatives and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.